Summit 4: Moderator

Peter J. Hulick, MD, MMSc, FACMG

Dr. Hulick is the Medical Director of the Mark R. Neaman Center for Personalized Medicine and Division Head for the Center for Medical Genetics at NorthShore University HealthSystem (NorthShore), which applies genetic analysis to prevention, diagnosis and treatment of inherited diseases and disorders. He joined NorthShore as an attending physician in medical genetics in 2008 and became Division Head of Medical Genetics in 2012.

Dr. Hulick also serves as a Clinical Assistant Professor in the Department of Human Genetics at the University of Chicago Pritzker School of Medicine. He has authored or co-authored more than 40 peer reviewed journal articles.

Dr. Hulick earned his medical degree from Jefferson Medical College in 2001. He completed a residency in internal medicine at St. Luke’s Hospital – Mayo Clinic, and completed a clinical fellowship in medical genetics at Harvard Medical School. He also earned a master’s degree in medical science from Harvard Medical School in 2007.

Summit 4: Panelists

Kelly E. Caudle, PharmD, PhD, BCPS, FCCP

Kelly E. Caudle, PharmD, PhD, BCPS is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Co-PI and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 25 gene-based clinical guidelines. In this position, Dr. Caudle oversees the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Children’s Research Hospital.
Jasmine Luzum, PharmD, PhD, BCPS

Dr. Luzum (formerly Talameh), PharmD, PhD, BCPS is an Assistant Professor at the University of Michigan College of Pharmacy. She received her PharmD summa cum laude from the University of Pittsburgh and her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill. She completed a Post-Doctoral Fellowship at the Ohio State University College of Medicine. She holds dual certification as a Board-Certified Pharmacotherapy Specialist (Board of Pharmacy Specialties) and an Applied Pharmacologist (American Board of Clinical Pharmacology). She has been a licensed pharmacist for over 10 years.

The goal of Dr. Luzum’s career is to improve drug outcomes and disparities in patients with cardiovascular disease. She works to accomplish that goal using a variety of clinical and translational research approaches, with an emphasis on pharmacogenomics and bioinformatics. Her research has been funded by the most prestigious sponsors (e.g., NIH and American Heart Association) and published in high impact journals (e.g., Cell Metabolism, Circulation: Heart Failure, Clinical Pharmacology & Therapeutics). She has taught pharmacogenetics to a variety of learners (e.g., from undergrads, to health professional students, to practicing clinicians) in a variety of formats (e.g., large lectures, small groups, and online).

Jeffrey Bishop, PharmD, MS, BCPP, FCCP

Jeffrey R. Bishop, PharmD, MS, BCPP, FCCP is associate professor in the Department of Experimental and Clinical Pharmacology at the University of Minnesota College of Pharmacy, and Adjunct Associate Professor in the Department of Psychiatry at the University of Minnesota Medical School. Dr. Bishop received his biology degree at Luther College in Decorah, Iowa. He then earned his Doctor of Pharmacy and Master’s in Clinical Investigation degrees from the University of Iowa Colleges of Pharmacy and Medicine along with a postdoctoral fellowship in clinical psychopharmacology and pharmacogenomics at the University of Iowa College of Pharmacy.

Dr. Bishop provides clinical and didactic education to pharmacy and other health sciences trainees. He maintains an active translational research program in psychopharmacology and pharmacogenomics examining genetic relationships with symptom improvement, side effects, and cognitive effects of medications as well as the clinical utility of pharmacogenetic testing in mental health. Dr. Bishop’s research has been supported through local, foundation, and NIH funding mechanisms.

Dr. Bishop is a member of the University of Minnesota Institute for Personalized Medicine as well as the University of Minnesota Precision Medicine Collaborative. He is an active member of the Clinical Pharmacogenetics Implementation Consortium with ongoing involvement in consensus guideline groups for medications used in mental health. Dr. Bishop is also active as an affiliate member of the Implementing Genomics in Practice (IGNITE) consortium pharmacogenetics interest group.
Jesse Ehrenfeld, MD, MPH

Jesse M. Ehrenfeld, MD, MPH, is a senior associate dean, tenured professor of anesthesiology and director of the “Advancing a Healthier Wisconsin Endowment” at the Medical College of Wisconsin. He also is professor of anesthesiology and health policy at Vanderbilt University. He was elected to the American Medical Association Board of Trustees in 2014.

Dr. Ehrenfeld divides his time among clinical practice, teaching, research and directing a $470-million statewide health philanthropy. He also has an appointment as an adjunct professor of surgery at the Uniformed Services University of the Health Sciences in Bethesda, Md., is a consultant to the World Health Organization Digital Health Technical Advisory Group and has served as special advisor to the 20th U.S. Surgeon General.

Dr. Ehrenfeld’s research, which focuses on understanding how information technology can improve surgical safety and patient outcomes, has been funded by the National Institutes of Health (NIH), the Department of Defense, the Robert Wood Johnson Foundation, the Anesthesia Patient Safety Foundation, and the Foundation for Anesthesia Education and Research.

His work has led to the presentation of more than 250 abstracts, as well as the publication of more than 200 peer-reviewed manuscripts. He is editor-in-chief of the Journal of Medical Systems and has co-authored 18 clinical textbooks. Dr. Ehrenfeld has received numerous awards for his research and is a recipient of several prestigious teaching awards.

Jill M. Kolesar, PharmD, MS

Dr. Kolesar is Professor of Pharmacy at the University of Kentucky and holds administrative positions at the Markey Cancer Center as the Director of the Precision Medicine Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Translational Oncology Program. She is a member of the Graduate Faculty in the College of Pharmacy, a member of the Markey Cancer Center and holds a joint appointment in the Division of Gynecologic Oncology in the College of Medicine.

Dr. Kolesar contributes substantial and sustained professional service to both the National Cancer Institute (NCI) and several pharmacy organizations. Serving on both the Early Phase and Cancer Prevention Central IRBs (CIRBs), multiple NCI study sections, and the Cancer Therapy and Evaluation Program (CTEP) Pharmacology task force and the Investigational Drug Steering Committee. Jill is a board-certified Pharmacotherapy Specialist and is a past President of the American College of Clinical Pharmacy (ACCP).

Dr. Kolesar’s research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 300 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $5 million in research funding from the NCI, American Cancer Society and other sources.
Michelle Springer, MS, CGC

Michelle Springer, MS, CGC, is an instructor and clinical genetic counselor with the University of Colorado Hereditary Cancer Clinic. She has been working as a certified genetic counselor for nearly 22 years, with graduate degrees in Genetics from Iowa State University and Medical Genetics/Genetic Counseling from Indiana University. Over the course of her career, Ms. Springer has worked in a number of different settings, including prenatal, cancer, pediatric and laboratory. During much of that time, she also did contract work for a cryobank. For the past 10 years, Ms. Springer’s interests and passion have been in the fields of oncology and personalized medicine. By understanding inherited genetic changes, she feels that patients can become empowered to be more proactive with their health care. She often tells patients, “While we can’t change our genes, we can potentially change the outcome.”

In addition to Ms. Springer’s clinical responsibilities, she plays an active role in the University of Colorado Denver Genetic Counseling Program. This includes teaching, clinical supervision of graduate students, and being a member of the Graduate School Admissions Committee. In 2019, she was awarded with the Outstanding Clinical Supervisor Award by the Association of Genetic Counseling Program Directors for her involvement with the genetic counseling program.